Treatment Of Patients With Social Anxiety Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

299

Participants

Timeline

Start Date

November 9, 2006

Primary Completion Date

September 5, 2007

Study Completion Date

September 5, 2007

Conditions
Social Phobia
Interventions
DRUG

GW876008

DRUG

paroxetine

Trial Locations (33)

1338

GSK Investigational Site, Sandvika

2301

GSK Investigational Site, Hamar

3630

GSK Investigational Site, Durban

7505

GSK Investigational Site, Tygerberg

7925

GSK Investigational Site, Observatory ,Cape Town

10024

GSK Investigational Site, New York

10629

GSK Investigational Site, Berlin

19063

GSK Investigational Site, Media

20100

GSK Investigational Site, Turku

20852

GSK Investigational Site, Rockville

26100

GSK Investigational Site, Rauma

26655

GSK Investigational Site, Westerstede

28832

GSK Investigational Site, Achim

30080

GSK Investigational Site, Smyrna

32806

GSK Investigational Site, Orlando

33173

GSK Investigational Site, Miami

35625

GSK Investigational Site, Hüttenberg

37075

GSK Investigational Site, Göttingen

48336

GSK Investigational Site, Farmington Hills

60181

GSK Investigational Site, Oakbrook Terrace

70110

GSK Investigational Site, Kuopio

90210

GSK Investigational Site, Beverly Hills

91506

GSK Investigational Site, Burbank

92591

GSK Investigational Site, Temecula

07110

GSK Investigational Site, Nutley

T6L 5X8

GSK Investigational Site, Edmonton

V1Y 2H4

GSK Investigational Site, Kelowna

E1V 3G5

GSK Investigational Site, Miramichi

L5M 4N4

GSK Investigational Site, Mississauga

0364

GSK Investigational Site, Oslo

SE-416 85

GSK Investigational Site, Gothenburg

SE-211 52

GSK Investigational Site, Malmo

SE-753 21

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY